{"id":"W4397007234","doi":"10.1016/j.esmoop.2024.103146","title":"159TiP TROPION-Breast04: Phase (ph) III study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (D) followed by adjuvant (adj) D vs standard of care (SoC) in treatment-naïve, triple-negative (TN) and HR-low/HER2- breast cancer (BC)","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Durvalumab; Medicine; Internal medicine; Standard of care; Adjuvant; Oncology; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001081219,0.0008408192,0.0007397411,0.0002417469,0.0002458151,0.000932791,0.0007765782,0.001115905,0.006979499],"category_scores_gemma":[0.0005792083,0.0003241591,0.001009763,0.0002973852,0.0004391741,0.00047329,0.0002961668,0.002518473,0.001625386],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001055506,"about_ca_system_score_gemma":0.001297116,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001431673,"about_ca_topic_score_gemma":0.004777686,"domain_scores_codex":[0.9997643,0.0001154701,0.000009467142,0.00003333432,0.00002625369,0.00005124174],"domain_scores_gemma":[0.999613,0.00006202571,0.00007496692,0.00002617003,0.00003069728,0.0001932044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6449574,0.0702976,0.00833042,0.001621817,0.00160622,0.0002196697,0.0002602789,0.003405883,0.07235965,0.0009899025,0.01874754,0.1772037],"study_design_scores_gemma":[0.49259,0.4697678,0.01288048,0.0001542393,0.000699287,0.0003909516,0.0001059413,0.001184807,0.006928212,0.0004485401,0.01481776,0.00003191885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9670173,0.005805482,0.000960045,0.001613305,0.0004121128,0.005143769,0.008163897,0.0002080346,0.0106761],"genre_scores_gemma":[0.9580215,0.004920296,0.002777789,0.003547353,0.0002192983,0.004981794,0.01350108,0.00008273133,0.01194812],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006979499,"threshold_uncertainty_score":0.02334875,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009822913088877542,"score_gpt":0.3140747849802658,"score_spread":0.3042518718913882,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}